Mainz Biomed B.V.(MYNZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MYNZ Mainz Biomed B.V.

Trading 02-09 10:59:55 EST

0.7635

-0.1819

-19.24%

High0.9899	Low0.6126	Vol577.58K
Open0.9500	D1 Closing0.9454	Amplitude39.91%
Mkt Cap6.92M	Tradable Cap6.88M	Total Shares9.06M
T/O456.01K	T/O Rate6.41%	Tradable Shares9.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MYNZ","market":"US","secType":"STK","nameCN":"Mainz Biomed B.V.","latestPrice":0.7635,"timestamp":1770652706369,"preClose":0.9454,"halted":0,"volume":577581,"delay":0,"changeRate":-0.19240533107679295,"floatShares":9008800,"shares":9060100,"eps":-8.39035,"marketStatus":"Trading","change":-0.1819,"latestTime":"02-09 10:59:55 EST","open":0.95,"high":0.9899,"low":0.6126,"amount":456006.70306206006,"amplitude":0.39909,"askPrice":0.7963,"askSize":100,"bidPrice":0.75,"bidSize":1530,"shortable":0,"etf":0,"ttmEps":-8.39035,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"listingDate":1635998400000,"exchange":"NASDAQ","adjPreClose":0.9454,"preHourTrading":{"tag":"盘前","latestPrice":0.9947,"preClose":0.9454,"latestTime":"09:28 EST","volume":6,"amount":5.9682,"timestamp":1770647330009,"change":0.0493,"changeRate":0.052147,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.9643,"preClose":0.9454,"latestTime":"19:06 EST","volume":947,"amount":911.1886,"timestamp":1770422819414,"change":0.0189,"changeRate":0.019992,"amplitude":0.019992},"volumeRatio":11.043796},"requestUrl":"/m/hq/s/MYNZ/tweets","defaultTab":"tweets","newsList":[{"id":"2606022688","title":"Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CEO and Director Guido Baechler","url":"https://stock-news.laohu8.com/highlight/detail?id=2606022688","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606022688?lang=en_us&edition=fundamental","pubTime":"2026-01-27 05:03","pubTimestamp":1769461402,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV has filed an initial statement of beneficial ownership. The filing names Guido Baechler as the beneficial owner, who serves as Chief Executive Officer and Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL788kwB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CEO and Director Guido Baechler","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2604948604","title":"Massive Insider Move: Major Investor Makes Colossal Bet on Mainz Biomed","url":"https://stock-news.laohu8.com/highlight/detail?id=2604948604","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604948604?lang=en_us&edition=fundamental","pubTime":"2026-01-17 10:03","pubTimestamp":1768615402,"startTime":"0","endTime":"0","summary":"New insider activity at Mainz Biomed B.V. ( ($MYNZ) ) has taken place on January 16, 2026. Significant shareholder Kevin Michael Donahue has dramat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/massive-insider-move-major-investor-makes-colossal-bet-on-mainz-biomed-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/massive-insider-move-major-investor-makes-colossal-bet-on-mainz-biomed-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2604916193","title":"Mainz Biomed NV Files Initial Beneficial Ownership Statement; Kevin Donahue Listed as 10% Owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2604916193","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604916193?lang=en_us&edition=fundamental","pubTime":"2026-01-17 04:38","pubTimestamp":1768595885,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Kevin Michael Donahue as a 10% owner of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLKWjlX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Mainz Biomed NV Files Initial Beneficial Ownership Statement; Kevin Donahue Listed as 10% Owner","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2603162076","title":"Mainz Biomed Unveils Pancreatic Cancer mRNA Blood Test Study Results at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2603162076","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603162076?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:17","pubTimestamp":1768396644,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a molecular genetic diagnostics company specializing in early cancer detection, has announced that it will present results from a verification study focused on pancreatic cancer at the upcoming 2026 Annual Meeting of the American Association for Cancer Research , scheduled to take place from April 17 to 22 in San Diego, California. The study involves a proprietary, blood-based mRNA biomarker signature combined with an AI-based modeling approach for the detection of ductal adenocarcinoma of the pancreas and differentiation from intraductal papillary mucinous neoplasms. The results are set to be presented at the AACR conference.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDLBjSDc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2601389887","title":"Mainz Biomed Provides Review of 2025 Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389887","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389887?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:15","pubTimestamp":1767622500,"startTime":"0","endTime":"0","summary":"Initiation of eAArly DETECT 2 - U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population in Preparation for ReconAAsense U.S. FDA Pivotal ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3212863/0/en/Mainz-Biomed-Provides-Review-of-2025-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCR","LU0456854461.SGD","BK4139","MYNZ","LU0266512127.USD","CRC","BK4213"],"gpt_icon":0},{"id":"2601881457","title":"Mainz Biomed Secures State Funding for Pancreatic Cancer Detection Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881457","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881457?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:17","pubTimestamp":1767619045,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV has announced that its pancreatic cancer early detection project has received government funding from the Investitions- und Strukturbank Rheinland-Pfalz . Under the ISB’s Innovation and Technology Funding Program, the state of Rhineland-Palatinate will cover up to 50% of the total project costs. This public funding highlights the scientific and societal significance of Mainz Biomed’s non-invasive blood test for the early detection of pancreatic cancer and is set to accelerate its development. No other beneficiary organizations were mentioned.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL5PSpqD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2588053403","title":"Mainz Biomed NV Partners with DoctorBox to Offer Home DNA Colorectal Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053403","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053403?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680526,"startTime":"0","endTime":"0","summary":"Mainz Biomed N.V., a molecular genetics diagnostic company specializing in early cancer detection, has announced a partnership with DoctorBox, one of Germany's leading digital health platforms. Through this collaboration, Mainz Biomed's DNA-based colorectal cancer screening test, ColoAlert, will be added to DoctorBox's portfolio of preventive healthcare services. The partnership aims to expand access to at-home colorectal cancer screening, with laboratory analysis provided by the European Oncology Lab. This move supports Mainz Biomed's European growth strategy and highlights the increasing role of digital solutions in preventive medicine.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDLb27KLW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","BK4588","IE00BKPKM429.USD","BK4585","LU2095319765.USD","MYNZ","IE00B3QW5Z07.USD","BK4139","LU2210149790.SGD","LU0314104364.USD","BK4112","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0},{"id":"2584937226","title":"Mainz Biomed Signs MOU with OncoVanguard8 to Launch ColoAlert in South America","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937226","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937226?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:03","pubTimestamp":1763470996,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV announced the signing of a Memorandum of Understanding  with OncoVanguard8 to introduce its DNA-based colorectal cancer screening test, ColoAlert, to South America, beginning with Peru. The agreement outlines commercial, legal, and regulatory terms, as well as the go-to-market strategy for the initial territory. The companies aim to finalize a distribution agreement in the coming weeks.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on November 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL83B0n0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","MYNZ","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BKPKM429.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2582797233","title":"Mainz Biomed NV Showcases Cancer Detection Solutions at MEDICA","url":"https://stock-news.laohu8.com/highlight/detail?id=2582797233","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582797233?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:02","pubTimestamp":1762952527,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV will participate in MEDICA 2025, one of the world's leading healthcare trade shows, taking place from November 17 to 20, 2025, in Düsseldorf, Germany. The company will showcase its flagship product, ColoAlert, a molecular stool-based screening test for early detection of colorectal cancer, along with other upcoming diagnostic solutions for early-stage cancer diagnosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL5qdMTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","LU2210150020.SGD","MYNZ","IE00B3QW5Z07.USD","BK4585","LU2095319765.USD","BK4588","BK4139","NDAQ"],"gpt_icon":0},{"id":"2582879240","title":"Mainz Biomed NV to Attend Annual Gastroenterological Working Group of Rhineland-Palatinate Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879240?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:04","pubTimestamp":1762779865,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1c2qcn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","BK4588","IE00BKPKM429.USD","BK4585","LU2095319765.USD","MYNZ","IE00B3QW5Z07.USD","BK4139","LU2210149790.SGD","LU0314104364.USD","BK4112","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0},{"id":"2575778778","title":"Mainz Biomed NV to Attend Maxim Growth Summit in New York City","url":"https://stock-news.laohu8.com/highlight/detail?id=2575778778","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575778778?lang=en_us&edition=fundamental","pubTime":"2025-10-15 21:01","pubTimestamp":1760533287,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a molecular genetics diagnostic company specializing in early cancer detection, will attend the 2025 Maxim Growth Summit on October 22-23, 2025, at The Hard Rock Hotel NYC. The company will participate in one-on-one meetings with institutional investors and senior Maxim analysts during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on October 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL2lS8p0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","MYNZ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","BK4139","LU2095319765.USD","BK4585","BK4588","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2573250289","title":"Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2573250289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573250289?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:00","pubTimestamp":1759928436,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV has announced positive topline results from a feasibility study evaluating a non-invasive blood-based screening test for the early detection of pancreatic cancer. The study assessed 18 proprietary mRNA biomarkers and identified a panel that demonstrated 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls within a 30-subject cohort. The results confirmed the clinical accuracy and utility of the biomarkers, and the company plans to initiate a larger clinical study using banked retrospective samples to further evaluate biomarker performance across different stages of pancreatic cancer. This future study will utilize next-generation sequencing technologies and is part of Mainz Biomed's broader strategy to develop accessible molecular diagnostics for early cancer detection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL1S70Qx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","MYNZ","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4588","BK4112","NDAQ","IE00B64PRP62.GBP","BK4139","IE00BKPKM429.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2572063611","title":"Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2572063611","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572063611?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:26","pubTimestamp":1759526786,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL5WWplZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2571634291","title":"Mainz Biomed NV to Showcase Future of Colorectal Cancer Screening at World Endoscopy Organization Committee Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2571634291","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571634291?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:01","pubTimestamp":1759233690,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a diagnostics company specializing in early cancer detection, will participate in the upcoming plenary session of the World Endoscopy Organization  Committee for Colorectal Cancer Screening on October 3, 2025, in Berlin. At the event, Dr. Lena Krammes, Senior Scientist at Mainz Biomed, will present the company's latest findings on RNA-based diagnostics for the detection and prevention of precancerous lesions, comparing early evidence from their RNA-based screening test to various FIT  cut-offs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL5b8cWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2570830092","title":"Mainz Biomed Reports Financial Results for First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2570830092","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570830092?lang=en_us&edition=fundamental","pubTime":"2025-09-27 05:34","pubTimestamp":1758922492,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Mainz Biomed B.V. ( ($MYNZ) ). On September 26, 2025, Mainz Biomed N.V. released its Management’s Discussion an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mainz-biomed-reports-financial-results-for-first-half-of-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mainz-biomed-reports-financial-results-for-first-half-of-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2569909117","title":"Mainz Biomed announces commercial launch of ColoAlert in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2569909117","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569909117?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:20","pubTimestamp":1758630027,"startTime":"0","endTime":"0","summary":"Mainz Biomed (MYNZ) announces the commercial launch of its flagship product, ColoAlert, in Switzerland. This milestone comes as the result of sever...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2569972547","title":"Mainz Biomed NV Announces Launch of ColoAlert® in Switzerland and Advances in eAArly DETECT 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2569972547","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569972547?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:01","pubTimestamp":1758628902,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced the commencement of the marketing of its primary product, ColoAlert, in Switzerland. This development marks a significant milestone following several key achievements by the company. Earlier this year, Mainz Biomed entered into a strategic partnership with labor team w ag, a leading diagnostics laboratory in Switzerland, to ensure the nationwide distribution of ColoAlert through an established and trusted network. The test has been officially registered and approved for distribution by Swissmedic, the Swiss agency for therapeutic products, enabling access to innovative colorectal cancer screening solutions for Swiss patients. In addition, a comprehensive technology transfer has been successfully completed, allowing the local processing and evaluation of ColoAlert samples in Goldach, Switzerland. Meanwhile, the company is advancing the recruitment for its feasibility study, which aims to include","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL2YvdJ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2565568298","title":"Mainz Biomed NV  expected to post a loss of $2.80 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2565568298","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565568298?lang=en_us&edition=fundamental","pubTime":"2025-09-05 20:34","pubTimestamp":1757075644,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV  expected to post a loss of $2.80 a share - Earnings Preview Mainz Biomed NV MYNZ.OQ, MYNZ.O is expected to  report resultson September 8 for the period ending March 31 2025The Mainz H","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nL8N3US0OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ"],"gpt_icon":0},{"id":"2564253804","title":"Mainz Biomed Announces Regulatory Approval of ColoAlert for Distribution in the United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2564253804","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564253804?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:02","pubTimestamp":1756814538,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a specialist in cancer early detection diagnostics, has announced that its ColoAlert test has received official registration from the Medicines and Healthcare products Regulatory Agency  in the United Kingdom. This milestone allows the test, which detects tumor DNA biomarkers in stool samples, to be distributed throughout the UK. This regulatory approval follows a technology partnership with EDX Medical Group plc and aims to complement existing colorectal cancer screening programs, enhancing accessibility and participation in early cancer detection efforts.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL4gSrTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2559604979","title":"Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2559604979","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559604979?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:03","pubTimestamp":1755086628,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL2XFlYt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://mainzbiomed.com","stockEarnings":[{"period":"1week","weight":-0.2055},{"period":"1month","weight":-0.2497},{"period":"3month","weight":-0.2783},{"period":"6month","weight":-0.3389},{"period":"1year","weight":-0.8696},{"period":"ytd","weight":-0.1559}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.1502},{"month":2,"riseRate":0.2,"avgChangeRate":-0.090897},{"month":3,"riseRate":0.5,"avgChangeRate":-0.077229},{"month":4,"riseRate":0.25,"avgChangeRate":-0.148679},{"month":5,"riseRate":0.25,"avgChangeRate":-0.028304},{"month":6,"riseRate":0,"avgChangeRate":-0.291752},{"month":7,"riseRate":0.75,"avgChangeRate":0.072818},{"month":8,"riseRate":0,"avgChangeRate":-0.153442},{"month":9,"riseRate":0,"avgChangeRate":-0.167388},{"month":10,"riseRate":0.25,"avgChangeRate":-0.076172},{"month":11,"riseRate":0.25,"avgChangeRate":-0.142413},{"month":12,"riseRate":0.6,"avgChangeRate":-0.115676}],"exchange":"NASDAQ","name":"Mainz Biomed B.V.","nameEN":"Mainz Biomed B.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mainz Biomed B.V.(MYNZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mainz Biomed B.V.(MYNZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mainz Biomed B.V.,MYNZ,Mainz Biomed B.V.股票,Mainz Biomed B.V.股票老虎,Mainz Biomed B.V.股票老虎国际,Mainz Biomed B.V.行情,Mainz Biomed B.V.股票行情,Mainz Biomed B.V.股价,Mainz Biomed B.V.股市,Mainz Biomed B.V.股票价格,Mainz Biomed B.V.股票交易,Mainz Biomed B.V.股票购买,Mainz Biomed B.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mainz Biomed B.V.(MYNZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mainz Biomed B.V.(MYNZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction